摘要
目的探讨重组腺相关病毒载体(rAAV-2-eGFP)是否可高效转导入骨髓间充质干细胞(BMSCs).方法从初发的急性髓性白血病(AML)患者骨髓中分离培养出BMSCs,在不同的感染复数(MOI=102,103,104,105,106,107)下用包含增强型绿色荧光蛋白(eGFP)的rAAV-2-eGFP感染BMSCs,寻找最佳的感染条件,并在转染后的不同时间点用倒置荧光显微镜以及流式细胞仪观察其表达情况.结果转染后10～14 d,eGFP在BMSCs中表达,转染效率为0.3%～2%,增加MOI亦不能明显增加转染效率.在MOI=105的条件下转染后观察了61 d,eGFP保持低水平长期稳定表达,在转染后的12～33 d,eGFP阳性的BMSCs从起始时的1.16%下降到(0.5～0.6)%,33～61 d一直维持在这一水平.结论rAAV-2-eGFP和BMSCs可用于体外基因治疗,但极低的转染效率可能是其进一步应用的障碍.
Objective To explore the possibility of using autologous bone marrow mesenchymal stem cells (BMSC) as a vehicle to deliver recombinant adeno-associated virus 2-mediated enhanced green fluorescent protein (rAAV-2-eGFP) in vitro, therefore to find an alternative solution for gene therapy of hematological malignancy. Methods BMSCs isolated from the bone marrow of patients with acute myelogenous leukemia (AML) at the onset of disease were infected by rAAV-2-eGFP at different multiplicity of infection (MOI=102, 103, 104, 105, 106, and 107, respectively). Phase-contrast fluorescent microscope and flow cytometry were employed to evaluate the expression of enhanced green fluorescent protein (eGFP). Results Ten to fourteen days after the transfection, eGFP expression began to be detected and the transfection efficiency ranged between 0.3% to 2%, which failed to be increased with the increase of MOI. The transduced eGFP could maintain a long-term stable expression in vitro in the 61 days of observation, and from 12 to 33 days after transfection, eGFP percentage underwent a decrease from the initial 1.16% to 0.5%-0.6% and maintained this expression level till 61 days after transfection. Conclusions rAAV can be used with BMSCs for in vitro gene therapy, but the poor transfection efficiency of these cells remains a significant obstacle for its further application.
出处
《第一军医大学学报》
CSCD
北大核心
2005年第3期281-284,共4页
Journal of First Military Medical University
基金
国家自然科学基金((No30100073)
广东省医学科研基金(A2000377)~~
关键词
重组腺相关病毒
骨髓间充干细胞
基因治疗
recombinant adeno-associated virus 2
bone marrow mesenchymal stem cells
gene therapy
